Chemomab Therapeutics Ltd.

CMMBNasdaqCM·Healthcare

$1.94▲ +0.14 (+7.93%)

Market openData as of 02:38 PM ET · 15-min delay

Analyst ratingnone

Price target$5.00

Consensus upside+157.7%

Every calculator, already run for CMMB

Open the full toolkit →

What is it worth?

P/E calculatorHow does this multiple compare to peers and its own history?Run →DCF calculatorTen years of free cash flow, discounted back to today.Run →Reverse DCFSolves the price backwards for the growth it already requires.Run →EV / EBITDAThe price with debt added and cash netted off.-0.6x PEG ratioThe multiple divided by the growth meant to justify it.Run →Graham numberGraham's ceiling from earnings and book value.Run →P/S ratioFor companies whose earnings are not the point yet.Run →

You have the numbers on CMMB. Get the argument.

A written report on which of these readings actually decide the outcome for Chemomab Therapeutics Ltd., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.

Key market data

Market cap$14.21M

P/E (TTM)—

Forward P/E-64.7x

Beta0.66

EPS (TTM)$-1.12

Dividend yield—

Volume122.0K

Avg volume133.7K

52-week range

$1.35$4.12

Analyst consensus

1 analysts covering CMMB

Buy1

Hold0

Sell0

Ownership & short interest

Institutions7.7%

Insiders11.1%

Short % float1.9%

Shares out$7.33M

About Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

HealthcareBiotechnologyIsrael

CMMB — frequently asked

Is CMMB a buy right now?

Wall Street's consensus rating on Chemomab Therapeutics Ltd. is none across 1 analysts, with a mean price target of $5.00 (+158% vs. the current $1.94). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.

Compare Chemomab Therapeutics Ltd. against related stocks

Explore additional stock overview pages and jump directly into full report generation for each symbol.

Sector peers

Most-followed names in the same sector.

LLY stock overview UNH stock overview JNJ stock overview MRK stock overview ABBV stock overview PFE stock overview AMGN stock overview ISRG stock overview

Nearby tickers

Additional public equities from our tracked universe.

CMG stock overview CME stock overview CMPR stock overview CMCT stock overview CMPS stock overview CMCSA stock overview CMRX stock overview

Market leaders

Large-cap symbols investors frequently compare.

AAPL stock overview MSFT stock overview NVDA stock overview AMZN stock overview GOOGL stock overview META stock overview TSLA stock overview JPM stock overview

Investor Guides For Chemomab Therapeutics Ltd.

Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.

Equity Research ChecklistsThe healthcare diligence checklist worth running before you size anything Earnings Question BanksThe healthcare earnings questions that matter after the headline beat Valuation PlaybooksWhat deserves the multiple in healthcare Red Flag WatchlistsThe healthcare red flags that quietly wreck the thesis

Generate your full CMMB research report

DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Chemomab Therapeutics Ltd., in minutes. 3 free reports included with every account — no credit card required.